People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| EyePoint Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $25.6M | $438.3M | 2020 |
John R. Landis, Ph.D., M.S. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John R. Landis, Ph.D., M.S. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Scott Jones | 1 | 11 |
| James Barry | 1 | 5 |
| Douglas Godshall | 1 | 4 |
| David Mazzo | 1 | 3 |
| Michael Rogers | 1 | 3 |
| Kristine Peterson | 1 | 3 |
| Jay Duker | 1 | 2 |
| George O. Elston | 1 | 2 |
| Nancy Lurker | 1 | 2 |
| Ronald W. Eastman | 1 | 2 |
| Wendy O. DiCicco | 1 | 1 |
| Dario Paggiarino, M.D. | 1 | 1 |
| Douglas W. Godshall | 1 | 1 |
| David R. Guyer, M.D. | 1 | 1 |
| Ye R. Liu | 1 | 1 |
| Dario S. Paggiarino | 1 | 1 |
| Leonard S. Ross | 1 | 1 |
| Goran Ando | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.